Onglyza(R) (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes (y 2)

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines.

AstraZeneca Forward-Looking Statement

The statements contained herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

The forward-looking statements reflect knowledge and information available at the date of the preparation of this press release and the Company undertakes no obligation to update these forward-looking statements.

Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things, those risk factors identified in the Company's Annual Report/Form 20-F for 2008. Nothing contained herein should be construed as a profit forecast.

ONGLYZA is a registered trademark of Bristol-Myers Squibb Company.

References

(1). Rosenstock J, et al. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2008; 10: 376-386.

(2). De Fronzo, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care. 2009 Sep;32(9):1649-55. Epub 2009 May 28

(3). Ravichandran S, et al. Saxagliptin added to a sulfonylurea is safe and more efficacious than up-titrating a sulfonylurea in patients with type 2 diabetes. Diabetologia. 2008; 51 (Suppl 1): S342, Abstract 858 (Poster presented at EASD. September 7-11,2008, Rome, Italy).

(4). Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with inadequately controlled type 2 diabetes. Diabetologia. 2008; 51 (Suppl 1):S342-S343, Abstract 859 (Poster presented at EASD. September 7-11, 2008, Rome, Italy).

(5). Jadzinsky M, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes, Obesity and Metabolism 2009; 11: 611-622

(6). Data on file

(7). International Diabetes Federation factsheet "diabetes prevalence" accessed 19 May, 2009 http://www.idf.org/diabetes-prevalence

(8). http://www.eatlas.idf.org/upload/files/T... (accessed 1601 hours September 15th 2009)

(9). IDF Global Guideline for type 2 diabetes 2005: Chapter 6: glucose control levels accessed 19 May, 2009 http://www.idf.org/webdata/docs/IDF%20GG...

    
    Media:
    Bristol-Myers Squibb,
    Carmel Hogan,
    +33-674-107-658,
    Carmel.hogan@bms.com
    OR
    AstraZeneca,
    Neil McCrae,
    +44-207-304-5045,
    Neil.mccrae@astrazeneca.com
    OR
    Christopher Sampson
    +44-207-304-5130
    Christopher.sampson@astrazeneca.com
    OR
    Jim Minnick
    +1-302-886-5135,
    Jim.minnick@astrazeneca.com
    Investors:
    Bristol-Myers Squibb,
    John Elicker,
    +1-609-252-4611,
    John.elicker@bms.com
    OR
    AstraZeneca,
    Karl J. Hard,
    +44-20-7304-5322,
    Karl.j.hard@astrazeneca.com
    OR
    Jonathan Hunt
    +44-777-570-4032,
    Jonathan.hunt@astrazeneca.com
    OR
    Edward Seage
    +1-302-886-4065
    Edward.seage@astrazeneca.com
    OR
    Jorgen Winroth
    +1-212-579-0506
    Jorgen.winroth@astrazeneca.com

Media: Bristol-Myers Squibb, Carmel Hogan, +33-674-107-658, Carmel.hogan@bms.com OR AstraZeneca, Neil McCrae, +44-207-304-5045, Neil.mccrae@astrazeneca.com OR Christopher Sampson, +44-207-304-5130, Christopher.sampson@astrazeneca.com OR Jim Minnick, +1-302-886-5135, Jim.minnick@astrazeneca.com; Investors: Bristol-Myers Squibb, John Elicker, +1-609-252-4611, John.elicker@bms.com OR AstraZeneca, Karl J. Hard, +44-20-7304-5322, Karl.j.hard@astrazeneca.com OR Jonathan Hunt, +44-777-570-4032, Jonathan.hunt@astrazeneca.com OR Edward Seage, +1-302-886-4065, Edward.seage@astrazeneca.com OR Jorgen Winroth, +1-212-579-0506, Jorgen.winroth@astrazeneca.com